New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: In vivo animal studies

Current Pharmaceutical Design

Volumn 16, Issue 6, 2010, Pages 653-659

  Giannola, L I ^a   Paderni, C ^a   De Caro, V ^a   Florena, A M ^a   Wolff, A ^b   Campisi, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b ASSUTA MEDICAL CENTER   (Israel)

Author keywords

Alzheimer disease; Galantamine; Transbuccal drug delivery

Indexed keywords

GALANTAMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; FEMALE; HISTOLOGY; IN VIVO STUDY; IONTOPHORESIS; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PUNCH BIOPSY; SINGLE DRUG DOSE; SWINE; AGED; ANIMAL; BUCCAL DRUG ADMINISTRATION; COMPARATIVE STUDY; DEVICES; DRUG EFFECTS; HUMAN; METABOLISM; MOUTH MUCOSA; ORAL DRUG ADMINISTRATION; PILOT STUDY; PROCEDURES; TRENDS;

ADMINISTRATION, BUCCAL; ADMINISTRATION, ORAL; AGED; ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; GALANTAMINE; HUMANS; MOUTH MUCOSA; PILOT PROJECTS; SWINE;

EID: 77950267129     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883804     Document Type: Article

References (15)

1. Pathan SA, Iqbal Z, Sahani JK, Talegaonkar S, Khar RK, Ahmad FJ. Buccoadhesive drug delivery systems-extensive review on recent patents. Recent Pat Drug Deliv Formul 2008; 2: 177-188
2. Buffum MD, Buffum JC. Dementia treatment update. Geriatr Nurs 2005; 26: 74-78
3. Singh B, O'Brien JT. When should drug treatment be started for people with dementia? Maturitas 2009; 62: 230-234
4. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 2001; 49: 289-299
5. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-1290
6. Litvinenko IV, Odinak MM, Mogil'naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol 2008; 38: 937-945
7. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD001747.
8. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024-2035
9. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276
10. Tariot PN. Maintaining cognitive function in Alzheimer disease: how effective are current treatments? Alzheimer Dis Assoc Disord 2001; 15: S26-S33.
11. Wang L, Cui Y. Developments of chronobiology abroad. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2005; 22: 185-188
12. Scholz OA, Wolff A, Schumacher A, Giannola LI, Campisi G, Ciach T, et al. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov Today 2008; 13: 247-253
13. De Caro V, Giandalia G, Siragusa MG, Paderni C, Campisi G, Giannola LI. Evaluation of galantamine transbuccal absorption by reconstituted human oral epithelium and porcine tissue as buccal mucosa models: part I. Eur J Pharm Biopharm 2008; 70: 869-873
14. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324
15. Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998; 40: 1-12.